UBS analyst Eliana Merle maintains $Apellis Pharmaceuticals (APLS.US)$ with a buy rating, and adjusts the target price from $83 to $45.
According to TipRanks data, the analyst has a success rate of 39.4% and a total average return of -5.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Apellis Pharmaceuticals (APLS.US)$'s main analysts recently are as follows:
Following the Q3 report, there's an identification of a distinct opportunity to develop a new thesis for 'post-GA' that is firmly rooted in the strong belief in the potential of C3G and IC-MPGN. The data for these are considered exceptionally robust and are viewed as superior to that of the oral competitor, especially in a wider context.
Following Apellis's report of Q3 Syfovre revenues that did not meet expectations, there remains anticipation for further insights into the geographic atrophy market's scope. Despite this, the valuation at present appears to underestimate the prospective market size, with the prospective introduction in C3G/IC-MPGN possibly mitigating the more gradual growth observed in the GA segment.
Apellis disclosed third-quarter results, which reflected a decrease in Syfovre revenue due to modest growth in vial numbers alongside a reduction in net pricing and heightened competition.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
瑞士銀行分析師Eliana Merle維持$Apellis Pharmaceuticals (APLS.US)$買入評級，並將目標價從83美元下調至45美元。
根據TipRanks數據顯示，該分析師近一年總勝率為39.4%，總平均回報率為-5.4%。
此外，綜合報道，$Apellis Pharmaceuticals (APLS.US)$近期主要分析師觀點如下：
繼第三季度報告之後，人們發現了一個難得的機會，可以爲 「後GA」 提出新論點，該論點堅定地植根於對C3G和IC-MPGN潛力的堅定信念。這些數據被認爲異常可靠，被認爲優於口頭競爭對手的數據，尤其是在更廣泛的背景下。
繼Apelis報告第三季度Syfovre收入未達到預期之後，人們仍有望進一步了解地域萎縮市場的範圍。儘管如此，目前的估值似乎低估了潛在的市場規模，預期引入C3G/IC-MPGN可能會緩解GA細分市場中更爲緩慢的增長。
Apellis披露了第三季度業績，這反映了Syfovre收入的減少，這是由於小瓶數量的溫和增長以及淨定價的下降和競爭的加劇。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
